Literature DB >> 31566378

Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.

Rama K Mishra1,2, Kristine K Deibler3, Matthew R Clutter4,5, Purav P Vagadia1, Matthew O'Connor3, Gary E Schiltz1,2,5, Raymond Bergan6, Karl A Scheidt1,2,3,4,5.   

Abstract

MEK4, mitogen-activated protein kinase kinase 4, is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. With advances in both computer and biological high-throughput screening, selective chemical entities can be discovered. Structure-based quantitative structure-activity relationship (QSAR) modeling often fails to generate accurate models due to poor alignment of training sets containing highly diverse compounds. Here we describe a highly predictive, nonalignment based robust QSAR model based on a data set of strikingly diverse MEK4 inhibitors. We computed the electrostatic potential (ESP) charges using a density functional theory (DFT) formalism of the donor and acceptor atoms of the ligands and hinge residues. Novel descriptors were then generated from the perturbation of the charge densities of the donor and acceptor atoms and were used to model a diverse set of 84 compounds, from which we built a robust predictive model.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31566378      PMCID: PMC6817392          DOI: 10.1021/acs.jcim.9b00490

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  40 in total

1.  R-group template CoMFA combines benefits of "ad hoc" and topomer alignments using 3D-QSAR for lead optimization.

Authors:  Richard D Cramer
Journal:  J Comput Aided Mol Des       Date:  2012-06-04       Impact factor: 3.686

2.  A comparison of methods for modeling quantitative structure-activity relationships.

Authors:  Jeffrey J Sutherland; Lee A O'Brien; Donald F Weaver
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

3.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Authors:  Kristine K Deibler; Rama K Mishra; Matthew R Clutter; Aleksandar Antanasijevic; Raymond Bergan; Michael Caffrey; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

4.  Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using Topomer CoMFA.

Authors:  Richard D Cramer; Phillip Cruz; Gunther Stahl; William C Curtiss; Brian Campbell; Brian B Masek; Farhad Soltanshahi
Journal:  J Chem Inf Model       Date:  2008-11       Impact factor: 4.956

Review 5.  Through the "gatekeeper door": exploiting the active kinase conformation.

Authors:  Fabio Zuccotto; Elena Ardini; Elena Casale; Mauro Angiolini
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

6.  Template CoMFA: the 3D-QSAR Grail?

Authors:  Richard D Cramer; Bernd Wendt
Journal:  J Chem Inf Model       Date:  2014-01-30       Impact factor: 4.956

7.  The use of atomic charges and orbital energies as hydrogen-bonding-donor parameters for QSAR studies: comparison of MNDO, AM1 and PM3 methods.

Authors:  T Ghafourian; J C Dearden
Journal:  J Pharm Pharmacol       Date:  2000-06       Impact factor: 3.765

8.  Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.

Authors:  Kristine K Deibler; Gary E Schiltz; Matthew R Clutter; Rama K Mishra; Purav P Vagadia; Matthew O'Connor; Mariam Donny George; Ryan Gordon; Graham Fowler; Raymond Bergan; Karl A Scheidt
Journal:  ChemMedChem       Date:  2019-02-19       Impact factor: 3.466

Review 9.  Toxicity modeling and prediction with pattern recognition.

Authors:  S Wold; W J Dunn; S Hellberg
Journal:  Environ Health Perspect       Date:  1985-09       Impact factor: 9.031

10.  Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.

Authors:  Janet M Pavese; Irene M Ogden; Eric A Voll; Xiaoke Huang; Li Xu; Borko Jovanovic; Raymond C Bergan
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

View more
  2 in total

Review 1.  Non-'classical' MEKs: A review of MEK3-7 inhibitors.

Authors:  Ada J Kwong; Karl A Scheidt
Journal:  Bioorg Med Chem Lett       Date:  2020-04-23       Impact factor: 2.823

2.  Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma.

Authors:  Ada J Kwong; Thao N D Pham; Hannah E Oelschlager; Hidayatullah G Munshi; Karl A Scheidt
Journal:  ACS Med Chem Lett       Date:  2021-09-15       Impact factor: 4.632

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.